Grail Stock Is Deeply Oversold on Cancer Test Failings. Is There Any Hope Left to Buy the Dip?

Grail (GRAL) shares were cut in half on Feb. 20 after the biotech firm said its highly anticipated NHS-Galleri clinical trial failed to meet its primary endpoint. As retail and institutional investors bailed on GRAL today, its 14-day relative strength index (RSI) crashed to 24, indicating a technical rebound was likely in the near term. More News from Barchart Still, investors are recommended against buying the dip in Grail stock, even though it looks like a bargain at about $49. www.barchart.com Sho ...